Acquisition proposal for 9.50% of Med Therapy Biotechnology Inc., USA stands terminated

Sudarshan Pharma Industries has informed the exchanges that the proposal to acquire 9.50% equity shares of common stock of Med Therapy Biotechnology Inc., USA stands terminated.

Wed 7 Oct 2026

Proposed Stake Acquisition Terminated

9.50% equity shares of common stock of Med Therapy Biotechnology Inc., USA

Promoter Proposals Terminated

Mr. Hemal Mehta and Mr. Sachin Mehta to acquire 1.50% each of the equity shares of common stock of Med Therapy

Continuation Of Earlier Letters

letters dated 5th September 2026 and 15th September 2026

Sudarshan Pharma Industries Ltd has told the stock exchanges that a proposed overseas share purchase will not go ahead.

What the update says

• The proposal to acquire 9.50% of the equity shares of common stock of Med Therapy Biotechnology Inc., USA stands terminated.
• A separate proposal by Mr. Hemal Mehta (Chairman & Managing Director) and Mr. Sachin Mehta (Joint Managing Director), who are Promoters of the company, to acquire 1.50% each of the equity shares of common stock of Med Therapy also stands terminated.

Where this fits

This intimation is in continuation of the company's earlier letters dated 5th September 2026 and 15th September 2026, which had set out the same acquisition plan. The company has now informed the market that the proposal covered in those letters is not going ahead.

How a retail investor might read it

• The plan described earlier is not being completed, so the stake in Med Therapy Biotechnology Inc., USA that was proposed to be bought does not come into the company's hands.
• Two sets of buyers were involved: the company itself for 9.50%, and the two promoter-directors for 1.50% each. Both parts of the plan have been called off together.
• The word used by the company is that the proposal "stands terminated".

What the numbers tell you

• 9.50% was the stake the company had proposed to acquire.
• 1.50% each was the stake each of the two promoter-directors had proposed to acquire.

Investors who track the company's acquisition pipeline may want to note that this particular proposal is no longer active.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.